CapsoVision (NASDAQ:CV) Shares Gap Down – What’s Next?

CapsoVision, Inc. (NASDAQ:CV) gapped down prior to trading on Thursday . The stock had previously closed at $11.80, but opened at $10.78. CapsoVision shares last traded at $12.38, with a volume of 1,797,496 shares trading hands.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on CV. Zacks Research upgraded shares of CapsoVision to a “hold” rating in a research report on Wednesday, November 5th. Weiss Ratings reissued a “sell (e)” rating on shares of CapsoVision in a research note on Monday. Roth Capital set a $7.00 price objective on CapsoVision in a report on Tuesday, November 4th. Finally, Benchmark reissued a “speculative buy” rating on shares of CapsoVision in a research note on Friday, November 14th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $6.00.

CapsoVision Price Performance

The firm’s 50 day moving average price is $5.35.

CapsoVision (NASDAQ:CV) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.03). The company had revenue of $3.54 million during the quarter.

Hedge Funds Weigh In On CapsoVision

An institutional investor recently bought a new position in CapsoVision stock. Citadel Advisors LLC bought a new stake in CapsoVision, Inc. (NASDAQ:CV) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 23,735 shares of the company’s stock, valued at approximately $115,000. Citadel Advisors LLC owned about 0.05% of CapsoVision as of its most recent filing with the Securities and Exchange Commission (SEC).

About CapsoVision

We are a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in our capsule endoscopy solutions to identify abnormalities of the gastrointestinal (“GI”) tract for diagnostic and screening purposes. We developed our first capsule endoscope system, currently comprising the CapsoCam Plus single-usecapsule and the CapsoCloud and CapsoView software, to panoramically visualize the small-bowel mucosa to investigate abnormalities such as obscure GI bleeding and Crohn’s disease.